Serum MiRNA-27a as potential diagnostic nucleic marker for breast cancer

Swellam, Menha; Zahran, Rasha; Ghonem, Samar Ayman; Abdel-Malak, Camelia

doi:10.1080/13813455.2019.1616765

Cited by 20 publications

(19 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It was also significantly higher in BC patients compared to patients with benign breast lesions. Our results were consistent with the results of a study done by Swellam et al 26 in which miR-27a expression level was determined among three groups: BC patients, patients with benign BC patients and healthy controls, and its expression level was significantly higher in primary BC patients followed by benign breast patients while its level among the healthy individuals was the lowest.…”

Section: Discussionsupporting

confidence: 92%

“…This was consistent with the study done by Swellam et al which reported significant link between expression of miR-27a and the clinical stages of BC. 26 A study done by Tang et al 39 reported that the expression of miR-27a is strongly correlated with the clinical stages and overall survival times of patients with BC. Raeisi et al also reported that overexpression of miR-27a was associated with shorter disease-free survival and the overall survival of BC patients.…”

Section: Discussionmentioning

confidence: 99%

“…Our results were in agreement with Swellam et al who reported that serum miR-27a had sensitivity 92%, specificity 92% and AUC of 0.955. 26 It is concluded that measuring miR-27a in peripheral blood may be a promising tool for detection of early stages of BC. Plasma miR-27a level may have a potential value for discrimination of malignant cases from nonmalignant cases with better diagnostic performance than serum CEA and CA 15-3.…”

Section: Discussionmentioning

confidence: 99%

“…Fluorescence measurement was made at every cycle. 26 Specific amplification of miRNA was ensured through analyzing the melting curves. Cycle threshold (Ct) value was defined as the cycle number in which there is the first detectable increase in fluorescence signals above a defined threshold.…”

Section: Quantification Of Mature Mirnas Using Qrt-pcrmentioning

confidence: 99%

See 3 more Smart Citations

Diagnostic values of microRNA 27a in breast cancer patients

Osama

Jabir

Abdel-Rahman

et al. 2021

EJI

View full text Add to dashboard Cite

Breast cancer is one of the most malignant tumors in women across the globe. Diagnosis of breast cancer at early stages is essential to improve treatment outcomes and decrease mortality rates. There is a pressing need for new non-invasive biomarkers to improve early diagnosis of breast cancer. This study aims to assess plasma miR-27a for the early diagnosis of breast cancer. miR-27a was evaluated in a total of 95 blood samples, 40 newly diagnosed cancer patients, 20 patients with benign breast lesions, 20 females with positive family history for breast cancer and 15 apparently healthy controls, using quantitative real time polymerase chain reaction. Our results exhibited significantly higher expression level of plasma miR-27a in breast cancer patients (median= 8.3 and 19 fold change for early and late stages respectively) compared to controls, high risk group and benign group with (P <0.001) for each. Plasma miR-27a was significantly higher in late breast cancer (median=19 fold change) compared to early breast cancer (median= 8.3) with (P <0.001). There was no statistically significant difference of plasmamiR-27a levels in benign group (median=1.8 fold change) compared to both control group and high risk group. There was no statistically significant difference of plasma miR-27a levels in high risk group (median= 1.2 fold change) compared to control group (median= 1 fold change). We performed Receiver Operating Characteristic (ROC) analysis for discriminating malignant from non-malignant cases. Plasma miR-27a yielded an area under the curve (AUC) of 0.983 with sensitivity 97.5%, specificity 91% and accuracy 94%.We concluded that miR-27a expression level represents sensitive and specific non-invasive molecular biomarkers for diagnosis of breast cancer.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Quantification Of Mature Mirnas Using Qrt-pcrmentioning

confidence: 99%

See 2 more Smart Citations

Diagnostic values of microRNA 27a in breast cancer patients

Osama

Jabir

Abdel-Rahman

et al. 2021

EJI

View full text Add to dashboard Cite

show abstract

“…A study by Gao et al (2013) demonstrated that for the diagnosis of breast cancer, miR-21 exhibited much higher sensitivity and specificity (87.6 % and 87.3%, respectively) compared with CA153 and CEA, which had sensitivities of 22.47% and 15.73%, respectively. Similarly, two recent studies found that miR-27a, miR-29a, and miR-335 were superior to CEA and CA15.3 for the early diagnosis of breast cancer and miR-27a exhibited a higher specificity and accuracy for the detection of early-stage and low grade BC, suggesting that miR-27a is a potential biomarker for the early diagnosis of BC, particularly in high-risk patients with early-stage and low grade malignancies (Ali Ahmed et al, 2020;Swellam et al, 2021).…”

Section: Clinically Standard Biomarkers Vs Circulating Mirnasmentioning

confidence: 74%

Circulating microRNAs as Reliable Tumor Biomarkers: Opportunities and Challenges Facing Clinical Application

El‐Daly

Gouhar

Elmageed

2022

J Pharmacol Exp Ther

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are involved in the development of human malignancies and cells have the ability to secrete these molecules into extracellular compartments. Thus, cell-free miRNAs (circulating miRNAs) can potentially be used as biomarkers to evaluate pathophysiological changes. Although circulating miRNAs have been proposed as potential noninvasive tumor biomarkers for diagnosis, prognosis, and response to therapy, their routine application in the clinic is far from being achieved. This review focuses on the recent progress regarding the value of circulating miRNAs as noninvasive biomarkers, with specific consideration of their relevant clinical applications. In addition, we provide an in-depth analysis of the technical challenges that impact the assessment of circulating miRNAs. We also highlight the significance of integrating circulating miRNAs with the standard laboratory biomarkers to boost sensitivity and specificity.The current status of circulating miRNAs in clinical trials as tumor biomarkers is also covered.These insights and general guidelines will assist researchers in experimental practice to ensure quality standards and repeatability, thus improving future studies on circulating miRNAs.

show abstract